Who is affected by this change?

This affects Independence Blue Cross Rheumatology, Internal Medicine providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Sep 3, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.028j, Abatacept (Orencia®) for Injection for Intravenous Use

Independence Blue Cross·Rheumatology, Internal Medicine·Pharmacy

Effective date

Sep 3, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.028j for Abatacept (Orencia®) injection for intravenous use has been reissued. This is a pharmacy policy update that may affect coverage criteria or prior authorization requirements for this rheumatoid arthritis medication.

Action Required

Action needed

By September 3, 2025: Review updated Abatacept (Orencia®) IV injection policy at the source URL to identify any changes to coverage criteria or prior authorization requirements. Update billing workflows and provider notifications accordingly for Medicare Advantage patients requiring this medication.

Related policy hubs

Independence Blue Cross policies Rheumatology Internal Medicine